Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Evolus (0K16) Share Price & Analysis

0 Followers

0K16 Stock Chart & Stats

$14.58$0.00(0.00%)
At close: 4:30 PM GMT
$10$12.5$15Nov 4Nov 18Dec 2Dec 16Dec 30Jan 13Jan 27
Day’s Range
$14.58 - $14.58
52-Week Range
$14.58 - $14.58
Previous Close
$14.58
Volume
N/A
Average Volume (3M)
0
Market Cap
$450.74M
Enterprise Value
$652.57M
Total Cash (Recent Filing)
$41.70M
Total Debt (Recent Filing)
$165.59M
Price to Earnings (P/E)
―
Beta
2.01
Next Earnings
Mar 09, 2027 (Est.)
EPS Estimate
0.06
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And EBITDA

Sustained double-digit revenue growth alongside four consecutive quarters of positive adjusted EBITDA indicates improving operating leverage and commercial traction. This combination strengthens the path toward self-funded expansion, although continued execution is needed to convert growth into durable GAAP profitability.

Portfolio Expansion

Rapid Evolysse adoption and growth well above the broader filler market show that Evolus is building a second meaningful product platform beyond Jeuveau. A broader portfolio can deepen provider relationships, increase account productivity, and make revenue less dependent on one injectable category.

Customer Scale And Retention

A large provider base, high reorder rates, and a growing consumer membership platform support repeat utilization rather than purely one-time sales. These network and engagement effects can improve commercial efficiency, strengthen customer retention, and provide a durable foundation for future product launches.

Bears Say

Negative Equity And Leverage

Negative stockholders’ equity and substantial debt reduce financial flexibility and leave the company more exposed if operating improvement slows. The capital structure may require refinancing or additional capital, creating dilution and execution risk while profitability remains unproven.

Unproven Profitability And Cash Flow

Revenue growth has not yet translated into positive GAAP earnings or consistently positive operating cash generation. Persistent losses can constrain reinvestment and increase reliance on external financing, making margin expansion and disciplined spending important to the company’s longer-term durability.

FDA Promotional Compliance Risk

The FDA correspondence adds regulatory and compliance risk to the commercialization of Jeuveau, even though management said it was not a warning letter and did not restrict promotion. Additional scrutiny could raise oversight costs or constrain future marketing practices if concerns recur.

Evolus News

0K16 FAQ

What was Evolus’s price range in the past 12 months?
Evolus lowest share price was $14.58 and its highest was $14.58 in the past 12 months.
What is Evolus’s market cap?
Evolus’s market cap is $450.74M.
When is Evolus’s upcoming earnings report date?
Evolus’s next earnings report is estimated for Mar 09, 2027 (not yet confirmed), which is in 116 days.
How were Evolus’s earnings last quarter?
Evolus released its earnings results on Nov 04, 2026. The company reported -$0.045 earnings per share for the quarter, beating the consensus estimate of -$0.062 by $0.017.
Is Evolus overvalued?
According to Wall Street analysts Evolus’s price is currently Undervalued.
Does Evolus pay dividends?
Evolus pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Evolus dividends here
What is Evolus’s EPS estimate?
Evolus’s EPS estimate is 0.06.
How many shares outstanding does Evolus have?
Evolus has 66,188,370 shares outstanding.
What happened to Evolus’s price movement after its last earnings report?
Evolus reported an EPS of -$0.045 in its last earnings report, beating expectations of -$0.062. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Evolus?
Hedge funds hold Evolus shares: the largest hedge-fund position in Evolus is 1,121,277,089 shares, and hedge funds increased their holdings by 1.1M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology